nach oben

Zeitschrift für Rheumatologie

Erschienen in:

30.06.2016 | Rheumatoide Arthritis | Leitthema: Meilensteine in der Rheumatologie: 75 Bände Innovation

Biologika

verfasst von: Prof. Dr. J. R. Kalden

Erschienen in: Zeitschrift für Rheumatologie | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Auszug

Im Alter von 25 Jahren hatte Paul Ehrlich [1] einen Traum: „To develop magic bullets, chemicals and later antibodies which, by their complementarity to cells or substances would specifically anchor and thereby excert a specific influence there and only there.“ Um diesen Traum von Paul Ehrlich zur Therapie von tumor- und auch immunologischen Erkrankungen Wirklichkeit werden zu lassen, war es notwendig, eine neue Technologie zur Herstellung von „magic bullets“ zu entwickeln. Dies geschah in den 1980er-Jahren durch Cesar Milstein und George Köhler [2], die 1985 in Nature die Methode zur Herstellung von monoklonalen Antikörpern publizierten. Explosionsartig haben seit dieser Zeit monoklonale Antikörper und andere Immuntherapeutika Eingang in Diagnostik und Therapie unterschiedlichster Krankheitsbilder gefunden. …

Ehrlich P (1989) Festschrift des 7. Internationalen Kongresses für Immunologie, Berlin.

Köhler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256(5517):495–497CrossRefPubMed

Rothe A, Power BE, Hudson PJ (2008) Therapeutic advances in rheumatology with the use of recombinant proteins. Nat Clin Pract Rheumatol 4(11):605–614CrossRefPubMed

Windisch J (2015) Biosimilars versus Erstanbieterbiologika. Z Rheumatol 74(8):672–681CrossRefPubMed

Dörner T, Strand V, Castañeda-Hernández G, Ferraccioli G, Isaacs JD, Kvien TK, Martin-Mola E, Mittendorf T, Smolen JS, Burmester GR (2013) The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis 72(3):322–328CrossRefPubMed

Alten R (2015) Biosimilars in der Rheumatologie. Entwicklung und Ergebnisse klinischer Studien. Z Rheumatol 74:682–688CrossRefPubMed

Vaitla PM, McDermott EM (2010) The role of high-dose intravenous immunoglobulin in rheumatology. Rheumatology (Oxford) 49(6):1040–1048CrossRef

Nimmerjahn F, Ravetch JV (2007) The antiinflammatory activity of IgG: the intravenous IgG paradox. J Exp Med 204(1):11–15CrossRefPubMedPubMedCentral

Anthony RM, Ravetch JV (2010) A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J Clin Immunol 30(Suppl 1):S9–S14CrossRefPubMed

10.

Cantarovich D, Mauff B le, Hourmant M, Giral M, Denis M, Hirn M, Jacques Y, Soulillou JP (1989) Treatment of acute kidney rejection episodes with monoclonal antibody directed against IL2 receptor: a pilot study. Transplant Proc 21(1 Pt 2):1785–1786PubMed

11.

Cantarovich D, Mauff B le, Hourmant M, Giral M, Denis M, Jacques Y, Soulillou JP (1989) Anti-IL2 receptor monoclonal antibody (33B3.1) in prophylaxis of early kidney rejection in humans: a randomized trial versus rabbit antithymocyte globulin. Transplant Proc 21(1 Pt 2):1769–1771PubMed

12.

Herzog CH, Walker CH, Pichler W et al (1987) Monoclonal anti-CD4 in arthritis. Lancet 330:1461–1462CrossRef

13.

Horneff G, Burmester GR, Emmrich F, Kalden JR (1991) Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody. Arthritis Rheum 34(2):129–140CrossRefPubMed

14.

Horneff G, Emmrich F, Reiter C, Kalden JR, Burmester GR (1992) Persistent depletion of CD4+ T cells and inversion of the CD4/CD8 T cell ratio induced by anti-CD4 therapy. J Rheumatol 19(12):1845–1850PubMed

15.

Lubbe PA van der, Dijkmans BA, Markusse HM, Nässander U, Breedveld FC (1995) A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. Arthritis Rheum 38(8):1097–1106CrossRefPubMed

16.

Breedveld FC (1998) Monoclonal antibodies to CD4. Rheum Dis Clin North Am 24(3):567–578CrossRefPubMed

17.

Kremer JM, Russell AS, Emery P, Abud-Mendoza C, Szechinski J, Westhovens R, Li T, Zhou X, Becker JC, Aranda R, Peterfy C, Genant HK (2011) Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3‑year results from the AIM trial. Ann Rheum Dis 70(10):1826–1830CrossRefPubMedPubMedCentral

18.

Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, Birbara C, Box J, Natarajan K, Nuamah I, Li T, Aranda R, Hagerty DT, Dougados M (2005) Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 353(11):1114–1123 (Erratum in: (2005) N Engl J Med 353(21):2311)CrossRefPubMed

19.

Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H et al (1994) Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344(8930):1105–1110CrossRefPubMed

20.

Lipsky PE, Heijde DM van der, Clair StEW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN (2000) Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 343(22):1594–1602CrossRefPubMed

21.

Zink A, Manger B, Kaufmann J, Eisterhues C, Krause A, Listing J, Strangfeld A (2014) Evaluation of the RABBIT risk score for serious infections. Ann Rheum Dis 73(9):1673–1676CrossRefPubMed

22.

Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP, British Society for Rheumatology Biologics Register (2006) Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the british society for rheumatology biologics register. Arthritis Rheum 54(8):2368–2376CrossRefPubMed

23.

Chatzidionysiou K, Kristensen LE, Eriksson J, Askling J, Vollenhoven R van, ARTIS Group (2015) Effectiveness and survival-on-drug of certolizumab pegol in rheumatoid arthritis in clinical practice: results from the national Swedish register. Scand J Rheumatol 44(6):431–437CrossRefPubMed

24.

Dartel SA van, Fransen J, Kievit W, Flendrie M, Broeder AA den, Visser H, Hartkamp A, Laar MA van de, Riel PL van (2013) Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Ann Rheum Dis 72(6):895–900CrossRefPubMed

25.

Antoni C, Dechant C, Lorenz PDH-M, Wendler J, Ogilvie A, Lueftl M, Kalden-Nemeth D, Kalden JR, Manger B (2002) Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum 47(5):506–512CrossRefPubMed

26.

Antoni C, Krueger GG, Vlam K de, Birbara C, Beutler A, Guzzo C, Zhou B, Dooley LT, Kavanaugh A, IMPACT 2 Trial Investigators (2005) Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 64(8):1150–1157CrossRefPubMedPubMedCentral

27.

Mease PJ, Armstrong AW (2014) Effective management of psoriasis and psoriatic arthritis: insights on current and emerging therapies and enhanced professional collaboration. Semin Arthritis Rheum 44(3):e7–8CrossRefPubMed

28.

Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromnica-Ihle E, Kellner H, Krause A, Schneider M, Sörensen H, Zeidler H, Thriene W, Sieper J (2002) Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet 359(9313):1187–1193CrossRefPubMed

29.

Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M, Mpofu S, Richards HB, MEASURE 1 Study Group, MEASURE 2 Study Group (2015) Secukinumab, an interleukin-17 a inhibitor, in ankylosing spondylitis. N Engl J Med 373(26):2534–2548CrossRefPubMed

30.

Bosch F van den, Deodhar A (2014) Treatment of spondyloarthritis beyond TNF-alpha blockade. Best Pract Res Clin Rheumatol 28(5):819–827. doi:10.1016/j.berh.2014.10.019.CrossRefPubMed

31.

Krieckaert CL, Jamnitski A, Nurmohamed MT, Kostense PJ, Boers M, Wolbink G (2012) Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity. Arthritis Rheum 64(12):3850–3855CrossRefPubMed

32.

Mok CC, Kleij D van der, Wolbink GJ (2013) Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases. Clin Rheumatol 32(10):1429–1435CrossRefPubMed

33.

Vincent FB, Morand EF, Murphy K, Mackay F, Mariette X, Marcelli C (2013) Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis 72(2):165–178CrossRefPubMed

34.

Eng GP, Bouchelouche P, Bartels EM, Bliddal H, Bendtzen K, Stoltenberg M (2016) Anti-drug antibodies, drug levels, interleukin-6 and soluble TNF receptors in rheumatoid arthritis patients during the first 6 months of treatment with adalimumab or infliximab: a descriptive cohort study (in press)

35.

Zisapel M, Zisman D, Madar-Balakirski N, Arad U, Padova H, Matz H, Maman-Sarvagyl H, Kaufman I, Paran D, Feld J, Litinsky I, Wigler I, Caspi D, Elkayam O (2015) Prevalence of TNF-α blocker immunogenicity in psoriatic arthritis. J Rheumatol 42(1):73–78CrossRefPubMed

36.

Bijl AE van der, Breedveld FC, Antoni CE, Kalden JR, Kary S, Burmester GR, Beckmann C, Unnebrink K, Kupper H (2008) An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status. Clin Rheumatol 27(8):1021–1028CrossRefPubMedPubMedCentral

37.

Coates LC, Cawkwell LS, Ng NW, Bennett AN, Bryer DJ, Fraser AD, Emery P, Marzo-Ortega H (2008) Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis. Rheumatology (Oxford) 47(6):897–900CrossRef

38.

Schiff MH, Kempis J von, Goldblum R, Tesser JR, Mueller RB (2014) Rheumatoidarthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase. Ann Rheum Dis 73(12):2174–2177CrossRefPubMed

39.

Emery P, Gottenberg JE, Rubbert-Roth A, Sarzi-Puttini P, Choquette D, Taboada VM, Barile-Fabris L, Moots RJ, Ostor A, Andrianakos A, Gemmen E, Mpofu C, Chung C, Gylvin LH, Finckh A (2015) Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. Ann Rheum Dis 74(6):979–984CrossRefPubMed

40.

Kalden JR (2015) Pathogenic cells of rheumatic inflammation as the target of modern therapies. Z Rheumatol 74:8–13CrossRefPubMed

41.

Mease PJ, Genovese MC, Greenwald MW, Ritchlin CT, Beaulieu AD, Deodhar A, Newmark R, Feng J, Erondu N, Nirula A (2014) Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med 370(24):2295–2306CrossRefPubMed

42.

Genovese MC, Greenwald M, Cho CS, Berman A, Jin L, Cameron GS, Benichou O, Xie L, Braun D, Berclaz PY, Banerjee S (2014) A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors. Arthritis Rheumatol 66(7):1693–1704CrossRefPubMed

43.

Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Aelion JA, Lee SH, Codding CE, Kellner H, Ikawa T, Hugot S, Ligozio G, Mpofu S (2014) One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study. J Rheumatol 41(3):414–421CrossRefPubMed

44.

Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M, Mpofu S, Richards HB, MEASURE 1 Study Group, MEASURE 2 Study Group (2015) Secukinumab, an interleukin-17 A inhibitor, in ankylosing spondylitis. N Engl J Med 373(26):2534–2548CrossRefPubMed

45.

Wendling D, Racadot E, Wijdenes J (1993) Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol 20(2):259–262PubMed

46.

Genovese MC, Fleischmann R, Furst D, Janssen N, Carter J, Dasgupta B, Bryson J, Duncan B, Zhu W, Pitzalis C, Durez P, Kretsos K (2014) Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised phase IIb study. Ann Rheum Dis 73(9):1607–1615CrossRefPubMedPubMedCentral

47.

Smolen JS, Weinblatt ME, Sheng S, Zhuang Y, Hsu B (2014) Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2‑part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 73(9):1616–1625CrossRefPubMedPubMedCentral

48.

Semerano L, Thiolat A, Minichiello E, Clavel G, Bessis N, Boissier MC (2014) Targeting IL-6 for the treatment of rheumatoid arthritis: phase II investigational drugs. Expert Opin Investig Drugs 23(7):979–999CrossRefPubMed

49.

Burmester GR, Weinblatt ME, McInnes IB, Porter D, Barbarash O, Vatutin M, Szombati I, Esfandiari E, Sleeman MA, Kane CD, Cavet G, Wang B, Godwood A, Magrini F, EARTH Study Group (2013) Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Ann Rheum Dis 72(9):1445–1452CrossRefPubMed

50.

Takeuchi T, Tanaka Y, Close D, Godwood A, Wu CY, Saurigny D (2015) Efficacy and safety of mavrilimumab in Japanese subjects with rheumatoid arthritis: findings from a phase IIa study. Mod Rheumatol 25(1):21–30CrossRefPubMed

51.

Shanafelt T, Lanasa MC, Call TG, Beaven AW, Leis JF, LaPlant B, Bowen D, Conte M, Jelinek DF, Hanson CA, Kay NE, Zent CS (2013) Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL). Cancer 119(21):3788–3796CrossRefPubMedPubMedCentral

52.

Østergaard M, Baslund B, Rigby W, Rojkovich B, Jorgensen C, Dawes PT, Wiell C, Wallace DJ, Tamer SC, Kastberg H, Petersen J, Sierakowski S (2010) Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study. Arthritis Rheum 62(8):2227–2238CrossRefPubMed

53.

Taylor PC, Quattrocchi E, Mallett S, Kurrasch R, Petersen J, Chang DJ (2011) Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial. Ann Rheum Dis 70(12):2119–2125CrossRefPubMedPubMedCentral

54.

Richez C, Truchetet ME, Schaeverbeke T, Bannwarth B (2014) Atacicept as an investigated therapy for rheumatoid arthritis. Expert Opin Investig Drugs 23(9):1285–1294CrossRefPubMed

55.

Smolen JS, Weinblatt ME, Heijde D van der, Rigby WF, Vollenhoven R van, Bingham CO 3rd, Veenhuizen M, Gill A, Zhao F, Komocsar WJ, Berclaz PY, Ortmann R, Lee C (2015) Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study. Ann Rheum Dis 74(8):1567–1570CrossRefPubMed

56.

Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, Brik R, McCann L, Kasapcopur O, Rutkowska-Sak L, Schneider R, Berkun Y, Calvo I, Erguven M, Goffin L, Hofer M, Kallinich T, Oliveira SK, Uziel Y, Viola S, Nistala K, Wouters C, Cimaz R, Ferrandiz MA, Flato B, Gamir ML, Kone-Paut I, Grom A, Magnusson B, Ozen S, Sztajnbok F, Lheritier K, Abrams K, Kim D, Martini A, Lovell DJ, PRINTO, PRCSG (2012) Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 20;367(25):2396–2406CrossRef

57.

Benedetti F de, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, Cuttica R, Ravelli A, Schneider R, Woo P, Wouters C, Xavier R, Zemel L, Baildam E, Burgos-Vargas R, Dolezalova P, Garay SM, Merino R, Joos R, Grom A, Wulffraat N, Zuber Z, Zulian F, Lovell D, Martini A, PRINTO, PRCSG (2012) Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 20;367(25):2385–2395CrossRef

58.

Riethmüller G (2012) Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on. Cancer Immun 12:12PubMedPubMedCentral

59.

Topp MS, Göckbuget N, Stein AS (2015) Safety and activity of blinatumomab for adult patients with relapsed or refractory B‑precursor acute lymphoblastic leukaemia: a multi-centre, single-arm, phase 2 study. Lancet Oncol 16(4):e158 (Correction to (2015) Lancet Oncol 16:60)PubMed

60.

Fischer JA, Hueber AJ, Wilson S, Galm M, Baum W, Kitson C, Auer J, Lorenz SH, Moelleken J, Bader M, Tissot AC, Tan SL, Seeber S, Schett G (2015) Combined inhibition of tumor necrosis factor α and interleukin-17 as a therapeutic opportunity in rheumatoid arthritis: development and characterization of a novel bispecific antibody. Arthritis Rheumatol 67(1):51–62CrossRefPubMed

61.

Lembke W, Schlereth B, Bertschinger J, Grabulovski DD, Locher M (2015) CVA322: A clinical stage bispecific TNF/IL-17 A inhibitor for the treatment of inflammatory diseases. Presented at Annual European Congress of Rheumatology (EULAR), Rome, Italy, 10–13 June 2015.

62.

Caso F, Cantarini L, Lucherini OM, Sfriso P, Fioretti M, Costa L, Vitale A, Atteno M, Galeazzi M, Muscari I, Magnotti F, Frediani B, Punzi L, Rigante D (2014) Working the endless puzzle of hereditary autoinflammatory disorders. Mod Rheumatol 24(3):381–389CrossRefPubMed

63.

Ter Haar N, Lachmann H, Özen S, Woo P, Uziel Y, Modesto C, Koné-Paut I, Cantarini L, Insalaco A, Neven B, Hofer M, Rigante D, Al-Mayouf S, Touitou I, Gallizzi R, Papadopoulou-Alataki E, Martino S, Kuemmerle-Deschner J, Obici L, Iagaru N, Simon A, Nielsen S, Martini A, Ruperto N, Gattorno M, Frenkel J, Paediatric Rheumatology International Trials Organisation (PRINTO), Eurofever/Eurotraps Projects (2013) Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis 72(5):678–685 (May)CrossRefPubMed

64.

Zaiss MM, Frey B, Hess A, Zwerina J, Luther J, Nimmerjahn F, Engelke K, Kollias G, Hünig T, Schett G, David JP (2010) Regulatory T cells protect from local and systemic bone destruction in arthritis. J Immunol 184(12):7238–7246CrossRefPubMed

65.

Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, Mauri C (2004) Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 200(3):277–285CrossRefPubMedPubMedCentral

66.

Ellis SD, McGovern JL, Maurik A van, Howe D, Ehrenstein MR, Notley CA (2014) Induced CD8+FoxP3+ treg cells in rheumatoid arthritis are modulated by p38 phosphorylation and monocytes expressing membrane tumor necrosis factor α and CD86. Arthritis Rheumatol 66(10):2694–2705CrossRefPubMed

67.

Tabares P, Berr S, Römer PS, Chuvpilo S, Matskevich AA, Tyrsin D, Fedotov Y, Einsele H, Tony HP, Hünig T (2014) Human regulatory T cells are selectively activated by low-dose application of the CD28 superagonist TGN1412/TAB08. Eur J Immunol 44(4):1225–1236CrossRefPubMed

68.

Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355(10):1018–1028CrossRefPubMed

69.

Hünig T (2012) The storm has cleared: lessons from the CD28 superagonist TGN1412 trial. Nat Rev Immunol 12(5):317–318PubMed

70.

Kavanaugh A, Puig L, Gottlieb AB, Ritchlin C, You Y, Li S, Song M, Randazzo B, Rahman P, McInnes IB (2016) Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2). Ann Rheum Dis. doi:10.1136/annrheumdis-2015-209068.

71.

Papp KA, Sundaram M, Bao Y, Williams DA, Gu Y, Signorovitch JE, Wang Y, Valdes JM, Mulani PM (2014) Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III study. J Eur Acad Dermatol Venereol 28(6):790–798CrossRefPubMed

Titel: Biologika
verfasst von: Prof. Dr. J. R. Kalden
Publikationsdatum: 30.06.2016
Verlag: Springer Medizin
Schlagwörter: Rheumatoide Arthritis
Tocilizumab
Erschienen in: Zeitschrift für Rheumatologie / Ausgabe 6/2016
Print ISSN: 0340-1855
Elektronische ISSN: 1435-1250
DOI: https://doi.org/10.1007/s00393-016-0122-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2016

Standardisierte Outcomeparameter

Therapieresistente Zellen der B‑Zell-Linie

Transition von der Kinder- und Jugendrheumatologie in die internistische Rheumatologie

Klinische Immunologie in der Rheumatologie

Synoviale Fibroblasten